Charles River Laboratories Revenue 2006-2018 | CRL

Charles River Laboratories annual/quarterly revenue history and growth rate from 2006 to 2018. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Charles River Laboratories revenue for the quarter ending September 30, 2018 was $0.585B, a 26.08% increase year-over-year.
  • Charles River Laboratories revenue for the twelve months ending September 30, 2018 was $2.143B, a 16.1% increase year-over-year.
  • Charles River Laboratories annual revenue for 2017 was $1.858B, a 10.48% increase from 2016.
  • Charles River Laboratories annual revenue for 2016 was $1.681B, a 23.34% increase from 2015.
  • Charles River Laboratories annual revenue for 2015 was $1.363B, a 5.06% increase from 2014.
Charles River Laboratories Annual Revenue
(Millions of US $)
2017 $1,858
2016 $1,681
2015 $1,363
2014 $1,298
2013 $1,166
2012 $1,130
2011 $1,143
2010 $1,133
2009 $1,172
2008 $1,295
2007 $1,231
2006 $1,058
2005 $993
Charles River Laboratories Quarterly Revenue
(Millions of US $)
Q3 2018 $585
Q2 2018 $585
Q1 2018 $494
Q4 2017 $478
Q3 2017 $464
Q2 2017 $469
Q1 2017 $446
Q4 2016 $467
Q3 2016 $426
Q2 2016 $434
Q1 2016 $355
Q4 2015 $354
Q3 2015 $349
Q2 2015 $340
Q1 2015 $320
Q4 2014 $330
Q3 2014 $328
Q2 2014 $341
Q1 2014 $299
Q4 2013 $289
Q3 2013 $292
Q2 2013 $293
Q1 2013 $291
Q4 2012 $280
Q3 2012 $279
Q2 2012 $285
Q1 2012 $286
Q4 2011 $291
Q3 2011 $278
Q2 2011 $288
Q1 2011 $286
Q4 2010 $282
Q3 2010 $271
Q2 2010 $289
Q1 2010 $292
Q4 2009 $264
Q3 2009 $297
Q2 2009 $308
Q1 2009 $302
Q4 2008 $263
Q3 2008 $342
Q2 2008 $352
Q1 2008 $338
Q4 2007 $318
Q3 2007 $314
Q2 2007 $307
Q1 2007 $291
Q4 2006 $272
Q3 2006 $265
Q2 2006 $268
Q1 2006 $254
Q4 2005 $226
Q3 2005 $243
Q2 2005 $251
Q1 2005 $274
Sector Industry Market Cap Revenue
Medical Medical Services $6.010B $1.858B
Charles River Laboratories International, Inc. provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Their dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. At Charles River, they are passionate about their role in improving the quality of people's lives. Their mission, their excellent science and strong sense of purpose guide in all that they do, and they approach each day with the knowledge that their work helps to improve the health and well-being of many across the globe. Charles River Laboratories International, Inc. service areas are Basic research, discovery, safety and efficacy, clinical support and manufacturing.
Stock Name Country Market Cap PE Ratio
Express Scripts Holding (ESRX) United States $55.382B 11.45
ICON (ICLR) Ireland $7.220B 22.63
PRA Health Sciences (PRAH) United States $6.479B 26.45
Premier (PINC) United States $5.056B 17.16
INC Research Holdings (SYNH) United States $4.514B 18.22
HealthEquity (HQY) United States $3.874B 75.72
Teladoc (TDOC) United States $3.587B 0.00
NovoCure (NVCR) Jersey $3.317B 0.00
AMN Healthcare Services Inc (AMN) United States $2.641B 18.12
BioTelemetry (BEAT) United States $2.149B 37.97
Medpace Holdings (MEDP) United States $1.902B 23.53
IKang Healthcare (KANG) China $1.412B 70.10
Intrexon (XON) United States $1.138B 0.00
Healthways (TVTY) United States $1.070B 13.16
CareDx (CDNA) United States $1.067B 0.00
Natera (NTRA) United States $0.946B 0.00
China Cord Blood (CO) China $0.729B 20.00
Surgery Partners (SGRY) United States $0.612B 0.00
Apollo Medical Holdings (AMEH) United States $0.582B 0.00
Civitas Solutions (CIVI) United States $0.532B 9.66
Establishment Labs Holdings (ESTA) $0.485B 0.00
Interpace Diagnostics (IDXG) United States $0.029B 0.00
Cancer Genetics (CGIX) United States $0.015B 0.00
OpGen (OPGN) United States $0.008B 0.00
FORM Holdings (XSPA) United States $0.005B 0.00
Biocept (BIOC) United States $0.002B 0.00